Market Overview

Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate

Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate

The market’s skepticism around Aptinyx Inc’s (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler.

The Aptinyx Analyst: Christopher Raymond initiated coverage of Aptinyx with an Overweight rating and a price target of $10.

The Aptinyx Thesis: Apart from the PTSD candidate, another two modulators show “meaningful potential,” which could lend upside to the stock over the intermediate- to longer-term, Raymond said.

“We understand the skepticism around PTSD but objectively, NYX-783 is the most promising agent in this condition in decades… And with management guiding to initiation of a pivotal trial next year, we think any sign of tacit FDA endorsement of these data is likely to be stock-moving,” he wrote in a note.

“Alongside NYX-783, another high-potential NMDAR modulator is NYX-2925, which should restart P2 enrollment in painful diabetic peripheral neuropathy this quarter, with POC data by 2022,” the analyst added.

Combining these compounds, the worldwide end-user revenue estimates are $159 million, $372 million, $605 million, $867 million, and $1.1 billion for 2026 through 2030, respectively, Raymond said.

APTX Price Action: Shares of Aptinyx were down 2% to $2.92 at the time of publication Tuesday.

Latest Ratings for APTX

Nov 2020HC Wainwright & Co.MaintainsBuy
Nov 2020SVB LeerinkMaintainsOutperform
Oct 2020Cantor FitzgeraldMaintainsOverweight

View More Analyst Ratings for APTX
View the Latest Analyst Ratings


Related Articles (APTX)

View Comments and Join the Discussion!

Posted-In: Christopher Raymond Piper SandlerAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga

Latest Ratings

ENBWells FargoUpgrades46.0
ENLCWells FargoUpgrades4.0
NBLXWells FargoUpgrades12.0
NSWells FargoUpgrades
OMPWells FargoUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at